Clinical trials of prostate-specific membrane antigen radiopharmaceutical therapy

H Jadvar, PM Colletti - Journal of Nuclear Medicine Technology, 2023 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) theranostics has been a momentous triumph
for nuclear medicine. The recent approvals of PSMA-targeted imaging agents (68Ga-PSMA …

Acceleration of PSMA-targeted theranostics to the clinic: can common sense prevail?

J Czernin, M Eiber - Journal of Nuclear Medicine, 2017 - Soc Nuclear Med
The success of targeting and exploiting the prostate-specific membrane antigen (PSMA) for
diagnosis and radioligand therapy of prostate cancer has been remarkable. Unlike in early …

PSMA theranostics: current status and future directions

K Rahbar, A Afshar-Oromieh, H Jadvar… - Molecular …, 2018 - journals.sagepub.com
Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics
and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases …

Is the vision of radioligand therapy for prostate cancer becoming a reality? An overview of the phase III VISION trial and its importance for the future of theranostics

K Rahbar, L Bodei, MJ Morris - Journal of Nuclear Medicine, 2019 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) is of considerable interest as a target for
diagnostics and therapy of prostate cancer patients. PSMA-targeted imaging has …

[HTML][HTML] PSMA theranostics: Review of the current status of PSMA-targeted imaging and radioligand therapy

W Jones, K Griffiths, PC Barata, CJ Paller - Cancers, 2020 - mdpi.com
Prostate-specific membrane antigen (PSMA) has been the subject of extensive investigation
in the past two decades as a promising molecular target for prostate cancer (PCa). Its …

What is theranostics

WA Weber, H Barthel, F Bengel, M Eiber… - J Nucl …, 2023 - Soc Nuclear Med
The term theranostics has clearly become a buzzword. To a large extent, this is due to the
success of prostate-specific membrane antigen (PSMA)-targeted radioligands. These …

Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer

N Vahidfar, M Fallahpoor, S Farzanehfar… - … of Radioanalytical and …, 2019 - Springer
Many efforts have been made to introduce an appropriate radiopharmaceutical as a
theranostic agent for metastatic castration-resistant prostate cancer. Prostate-specific …

Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting

AK Miyahira, KJ Pienta, JW Babich, NH Bander… - The …, 2020 - Wiley Online Library
Abstract Introduction The Prostate Cancer Foundation (PCF) convened a PCF prostate‐
specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 …

[HTML][HTML] Prostate specific membrane antigen binding radiopharmaceuticals: current data and new concepts

O Sartor, A Baghian - Frontiers in Medicine, 2022 - frontiersin.org
Prostate specific membrane antigen (PSMA) represents a validated target for prostate
cancer therapeutics. The phase III VISION study with 177lutetium (177Lu)-PSMA-617 …

Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer …

C Schuchardt, J Zhang, HR Kulkarni… - Journal of Nuclear …, 2022 - Soc Nuclear Med
The objective of this study was to determine the safety, kinetics, and dosimetry of the 177Lu-
labeled prostate-specific membrane antigen (PSMA) small molecules 177Lu-PSMA I&T and …